Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Secreted frizzled-related protein 1 wikipedia , lookup
Protein adsorption wikipedia , lookup
Cell membrane wikipedia , lookup
G protein–coupled receptor wikipedia , lookup
Endomembrane system wikipedia , lookup
Protein–protein interaction wikipedia , lookup
Molecular neuroscience wikipedia , lookup
Drug design wikipedia , lookup
Cell-penetrating peptide wikipedia , lookup
Clinical neurochemistry wikipedia , lookup
RECEPTOR / TARGET DECONVOLUTION SPOTTING YOUR TARGET. Rapidly discover receptors and druggable targets Retrogenix discovers specific, biologically-relevant primary receptors and secondary targets by screening for interactions against >4,000 human plasma membrane proteins that are individually over-expressed in their native context in human cells. Test molecules are allowed to bind and then specific interactions with target receptors are identified and confirmed. PLASMA MEMBRANE TARGET •Uncover receptors for protein ligands, peptides and viruses •Deconvolute targets in phenotypic drug discovery Screen antibodies, proteins, viruses and small molecules •Identify any off-target liabilities RECENT SUCCESSES •Interactions via post-translational modifications – new cancer targeting strategy identifed2 “In less than two months Retrogenix was able to identify and confirm the target specificity of multiple antibodies (over 70% of antibodies provided).” •Breakthrough in malaria research – published in Nature3 Head of Antibody Discovery, Bayer •Target deconvolution for novel cancer antibodies – MedImmune project1 1 Molecular Cancer 14:147; 2015 2 Cancer Cell 28(4):500-514; 2015 3 Nature 498:502-5; 2013 WWW.RETROGENIX.COM OFF-TARGET PROFILING SPOTTING YOUR TARGET. Antibodies – ADCs – scFvs – CAR T cells – therapeutic proteins Screen for cell surface off-targets to: • Aid pre-clinical safety assessment • Explain unexpected PK • Prioritise promising antibody leads • Complement tissue cross-reactivity studies • Support IND regulatory submissions WHY RETROGENIX? •Unrivalled success rates •Versatile – wide range of molecules and detection tags •Low false positives/negatives •Rapid results •Scalable •Biologically relevant “… the Retrogenix method is a very promising tool for our concerted antibody and antigen discovery platforms.” Christoph Rader, Associate Professor Cancer Biology, Scripps Research Institute Award Winning Innovation Please contact Dr Jim Freeth on +44(0)7789 650932 or [email protected]